查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2009320

免疫球蛋白市场规模、份额、趋势和预测：按产品、应用、给药途径和地区划分，2026-2034年

Immunoglobulin Market Size, Share, Trends and Forecast by Product, Application, Mode of Delivery, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

2025年全球免疫球蛋白市场规模为172亿美元。展望未来，IMARC集团预测，该市场将以4.60%的复合年增长率从2026年增长至2034年，到2034年达到258亿美元。北美目前是该市场的主要驱动力，预计2025年将占据46.5%的市场。推动此市场成长的主要因素包括：免疫疾病发生率上升、老年人口成长、免疫疗法的持续进步、产品在神经病学和血液病学领域的应用不断扩大，以及人们对原发性免疫力缺乏缺陷症候群（PIDD）和其他自体免疫疾病的认识不断提高。

市场的主要驱动因素是免疫力缺乏疾病（例如原发性和续发性免疫力缺乏）盛行率的不断上升，这推动了对免疫球蛋白疗法的需求。此外，免疫球蛋白製剂的创新（例如皮下和静脉注射）以及正在进行的临床研究也在促进市场成长。例如，2024年10月22日，大冢製药公布了cibeprenimab治疗成人IgAN（免疫介导性肾小球肾炎）患者的III期VISIONARY试验的令人鼓舞的中期结果。该试验表明，与安慰剂相比，cibeprenimab在不影响安全性的前提下，显着降低了24小时尿蛋白肌酸酐比值（uPCR），并在9个月时达到了主要终点。此外，人们对自体免疫疾病的认识不断提高以及诊断率的上升，也促使免疫球蛋白作为一种有效治疗方法得到更广泛的应用。

由于重症肌无力、多灶性运动神经病变等罕见神经系统疾病的发生率不断上升，美国市场正经历显着增长，这推动了对免疫球蛋白疗法的需求。此外，美国拥有完善的医疗保健基础设施，且患者能够方便地获得昂贵的治疗，使其成为免疫球蛋白产品的重要市场。同时，美国有利的政策和完善的核准流程进一步扩大了免疫球蛋白疗法的可及性，确保了该领域的市场持续成长和创新。 2024年6月17日，格里福尔斯製药公司宣布其子公司Biotest的静脉注射免疫球蛋白疗法Yimmugo®获得美国食品药物管理局（食品药物管理局）核准，用于治疗原发性免疫力缺乏。这是Biotest首个获得FDA核准的治疗产品，由该公司位于德国德赖艾希的新建Next Level工厂生产。 Yimmugo®计划于2024年下半年在美国上市，预计将显着提升格里福尔斯集团的销售额，并支持其未来的成长策略。

免疫球蛋白市场趋势：

免疫系统疾病盛行率增加

原发性免疫力缺乏（PIDDs）、慢性脱髓鞘多发性神经炎（CIDP）和川崎病等免疫疾病发生率的上升是推动免疫球蛋白市场发展的主要趋势之一。例如， 新患者数约为每 10 万人 1-2 例。这些疾病会削弱人体的免疫系统，使其更容易受到感染疾病。随着免疫相关疾病患者人数的增加，对免疫球蛋白疗法的需求也随之增加。 PIDDs 包含 300 多种罕见疾病，在已开发国家和新兴国家都备受关注。早期诊断和治疗对于控制这些疾病至关重要，这也进一步增加了对作为主要治疗方案的免疫球蛋白的需求。

血浆衍生疗法的进展

血浆衍生疗法的持续进步是推动市场成长的关键因素。免疫球蛋白主要提取自人血浆。血浆采集和纯化技术的进步进一步提高了生产效率。这些创新有助于更可靠地供应免疫球蛋白产品。此外，生产过程的创新也提高了这些疗法的品质、安全性和有效性。皮下注射免疫球蛋白（SCIG）产品的开发，使患者能够在家中自行给药，提高了患者的便利性和治疗依从性。此外，不依赖血浆捐赠的重组免疫球蛋白产品的出现，有望缓解供应紧张，同时提供替代治疗方案，从而促进免疫球蛋白市场的成长。

应用范围扩展至各医学领域

免疫球蛋白疗法在各个医学领域的应用不断扩展，推动了市场成长。除了传统的免疫学用途外，免疫球蛋白目前也广泛应用于神经病学、血液病学，甚至肿瘤学领域。例如，在美国，2023年肿瘤治疗支出达到990亿美元，高于2019年的650亿美元。在神经病学领域，免疫球蛋白疗法越来越多地用于治疗Guillain-Barré二氏症候群、多发性硬化症和重症肌无力等疾病。在血液科领域，免疫球蛋白被用于治疗自体免疫溶血性贫血和特发性血小板减少紫斑症（ITP）。这些应用领域的拓展得益于正在进行的临床试验和研究，这些试验和研究探索了免疫球蛋白在更广泛疾病中的应用，从而对免疫球蛋白市场的前景产生了积极影响。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球免疫球蛋白市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依产品划分

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

第七章 市场区隔：依应用领域划分

  • 低丙种球蛋白血症
  • 慢性脱髓鞘多发性神经炎（CIDP）
  • 免疫不全症
  • 重症肌无力
  • 其他的

第八章 市场区隔：依交付方式划分

  • 静脉注射
  • 皮下注射

第九章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • ADMA Biologics Inc.
    • Baxter international Inc.
    • Biotest AG
    • CSL Limited
    • Grifols SA
    • Kedrion SpA
    • LFB SA
    • Octapharma AG
    • Sanquin Plasma Products BV
    • Takeda Pharmaceutical Company Limited
Product Code: SR112026A4505

The global immunoglobulin market size was valued at USD 17.2 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 25.8 Billion by 2034, exhibiting a CAGR of 4.60% during 2026-2034. North America currently dominates the market with 46.5% of the share in 2025. The market is primarily driven by the rising incidences of immune disorders, increasing geriatric population, ongoing advancements in immunotherapy treatments, expanding product employment in neurology and hematology, and growing awareness about primary immunodeficiency disorders (PIDD) and other autoimmune diseases.

The main driving factor of the market is the increased prevalence of immunodeficiency disorders, such as primary and secondary immunodeficiencies, raising the demand for immunoglobulin therapies. Moreover, ongoing clinical research, along with innovation in immunoglobulin formulations, such as subcutaneous and intravenous delivery methods, is providing an impetus to market growth. For instance, on October 22, 2024, Otsuka Pharmaceutical released promising interim results for their Phase 3 VISIONARY study regarding sibeprenlimab to treat adult patients with IgAN. The study met the primary endpoint after nine months by showing a clinically significant decrease in 24-hour uPCR compared with placebo, without compromising safety. Apart from this, rising awareness and diagnosis of autoimmune diseases have increased the usage of immunoglobulins as an effective treatment modality.

The market in the United States is experiencing significant growth due to the increasing incidence of rare neurological disorders, such as myasthenia gravis and multifocal motor neuropathy, which has fueled demand for immunoglobulin therapies. Apart from this, the presence of advanced healthcare infrastructure in the United States enabling better access to high-cost treatments, is positioning the country as a significant market for immunoglobulin products. Besides this, the implementation of favorable initiatives and tested approvals in the United States further enables wider access to immunoglobulin treatments, ensuring sustained market growth and innovation in this sector. On June 17, 2024, Grifols announced that its subsidiary, Biotest, secured U.S. FDA approval for Yimmugo, an intravenous immunoglobulin therapy for primary immunodeficiencies. This marks Biotest's first FDA-approved treatment, manufactured at its new "Next Level" facility in Dreieich, Germany. The U.S. launch of Yimmugo(R) in the latter half of 2024 is expected to significantly contribute to Grifols Group's sales and support its future growth strategy.

IMMUNOGLOBULIN MARKET TRENDS:

Increasing prevalence of immune disorders

The rising incidence of immune disorders, such as PIDD, c hronic inflammatory demyelinating polyneuropathy (CIDP), and Kawasaki disease , is one of the key trends driving the immunoglobulin market. For instance, the number of new cases per year of CIDP is about 1-2 per 100,000 people. These disorders weaken the body's immune system, making it more susceptible to infections. With a growing number of patients being diagnosed with immune-related conditions, the demand for immunoglobulin therapies is on the rise. PIDD, which comprises over 300 different rare conditions, is gaining increased attention in both developed and emerging economies. Early diagnosis and treatment are critical in managing these conditions, which is further increasing the immunoglobulin demand as the primary treatment option.

Advancements in plasma-derived therapies

Continual advancements in plasma-derived therapies are a significant growth-inducting factor for the market. Primarily, immunoglobulin is derived from human plasma. Technological advancements along the lines of plasma collection and purification further enhance production efficiency. These innovations contribute to a more reliable supply of immunoglobulin products. Additionally, innovations in manufacturing processes improve the quality, safety, and efficacy of these therapies. The development of SCIG products, which allow for self-administration at home, facilitates patient convenience and adherence to treatment. Furthermore, the emergence of recombinant immunoglobulin products, which do not rely on plasma donations, has the potential to alleviate supply constraints while offering an alternative therapeutic option, thereby supporting the immunoglobulin market growth.

Expanding applications in various medical fields

The expanding application of immunoglobulin therapies in various medical fields is providing an impetus to market growth. Beyond its traditional usage in immunology, immunoglobulin is widely employed in neurology, hematology, and even oncology. For instance, the United States spent USD 99 billion on oncology in 2023, up from USD 65 billion in 2019. For example, in neurology, immunoglobulin therapies are increasingly used to treat conditions like Guillain-Barre syndrome, multiple sclerosis, and myasthenia gravis. In hematology, immunoglobulins are used to manage autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura (ITP). These expanding applications are supported by ongoing clinical trials and research efforts exploring the use of immunoglobulins for a wider range of diseases, thus positively impacting the immunoglobulin market outlook.

IMMUNOGLOBULIN INDUSTRY SEGMENTATION:

Analysis by Product:

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

IgG leads the market with 42.2% of the share in 2025 due to its widespread therapeutic use and central role in the proper functioning of the immune system. As the most abundant antibody circulating in the bloodstream, IgG is indispensable in neutralizing pathogens and mediating immune responses; therefore, it forms an important component in the treatment of primary immunodeficiency diseases, autoimmune diseases, and a variety of infections. Its increasing global prevalence has increased the demand for IgG therapies. Advancements in IgG technology also include enhancement of its purity by extraction, and methods of administration with better efficiency have increased patient safety and acceptance toward it, resulting in adoption.

Analysis by Application:

  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Immunodeficiency Disease
  • Myasthenia Gravis
  • Others

In 2025, immunodeficiency diseases lead the market due to a high and increasingly large prevalence. Immunodeficiency diseases, which comprise primary immunodeficiency diseases, are characterized by a weakened immune system, with patients being very susceptible to infections. Immunoglobulin therapy has become a cornerstone in managing these conditions; it provides patients with essential antibodies that bolster their immune defense. The increase in the incidence of PIDs across the globe, in conjunction with improved diagnostics, raises demand for immunoglobulin products. Increased accessibility due to growth in healthcare infrastructure, as well as entry into specialty treatment centers, expands a patient's access for treatment.

Analysis by Mode of Delivery:

  • Intravenous Mode of Delivery
  • Subcutaneous Mode of Delivery

Intravenous mode of delivery leads the market with 46.5% of the share in 2025. The efficiency and application for treating numerous immune-related conditions provided by intravenous mode of delivery drives its usage in such treatments. Severe and acute conditions like primary immunodeficiency diseases (PIDs), Kawasaki disease, and some neurological disorders require the intravenous delivery of IVIG for its quick bioavailability and therapeutic impact. The growing incidence of these conditions, combined with improvements in the formulation of IVIG, which makes it safer and more convenient for patients, increases demand for this product. Healthcare providers and patients prefer the intravenous route, as it has been well-established to be effective in the treatment of life-threatening complications.

Analysis by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America leads the immunoglobulin market with 46.5% of the share, due to its advanced health care infrastructure, awareness regarding diseases, and significant expenditure towards research and development (R&D) activities. Its well-built diagnostic capabilities help to recognize the primary condition, that is, immune deficiencies and autoimmune disorders, and therefore create a regular demand for immunoglobulin therapies. Also, an increased older population at higher risk for immune-related disorders results in demand for immunoglobulin. The increasing incidence of primary immunodeficiency diseases, neurological disorders such as Guillain-Barre syndrome, and chronic inflammatory demyelinating polyneuropathy are driving growth in the market. The presence of key biopharmaceutical companies and facilitative regulatory environments make it easier for innovative immunoglobulin products to get through to the market. Positive recompense policies further boost market growth.

KEY REGIONAL TAKEAWAYS:

UNITED STATES IMMUNOGLOBULIN MARKET ANALYSIS

The US accounted for 83.30% of the overall North America immunoglobulin market share in 2025. Massive growth in the adoption of immunoglobulin treatments is being encouraged in the region due to increasing emphasis on developing advanced healthcare systems. The need for better patient outcomes results in significant investment in healthcare services and biopharmaceutical inventions, which ensures the availability of therapies regarding immune deficiencies. For instance, U.S. healthcare companies are securing venture capital deals of USD 15 Million plus are driving robust investment growth, focusing on innovation in medical technology to meet rising market demands. Expanded access to immunoglobulin products via specialized centers and ongoing improvements in administration techniques streamline the treatment process. Support for rare disease management and comprehensive insurance coverage further supports the adoption of treatments. Improved diagnostics are also instrumental, allowing for earlier detection and more targeted therapeutic interventions. Interdisciplinary collaboration between healthcare providers and research institutes is fueling clinical development and optimizing patient care. Efforts to educate healthcare professionals about the most advanced treatments are empowering the wide usage of immunoglobulin therapies. As funding grows, healthcare systems are better equipped to integrate immunoglobulin into treatment protocols, reinforcing its role in addressing immune-related conditions.

ASIA PACIFIC IMMUNOGLOBULIN MARKET ANALYSIS

The rise in immunoglobulin utilization in the region is due to the increase in conditions which require immune system modulation. According to National Library of Medicine, the estimated number of incident cases of cancer in India for the year 2022 was found to be 14,61,427. With more patients diagnosed at advanced stages, the demand for supportive therapies has increased. Expanding medical research focused on adjunctive treatments complements chemotherapy and radiotherapy. Enhanced clinical trial frameworks pave the way for innovations, ensuring tailored solutions for unique patient needs. Hospitals are incorporating cutting-edge biotherapeutic products into treatment guidelines, reflecting a commitment to comprehensive care. Strategic alliances among healthcare providers and educational institutions are fostering awareness regarding immunoglobulin therapies. Upgraded healthcare technologies facilitate the integration of these treatments into routine care. Such advancements, along with patient-centric models, are creating an environment conducive to greater therapeutic adoption. Increased accessibility to specialized medicines is empowering practitioners to incorporate them into a broader spectrum of treatment approaches.

EUROPE IMMUNOGLOBULIN MARKET ANALYSIS

The aging demographic in the region significantly influences the growing application of immunoglobulin therapies. For instance, Europe's ageing population is on the rise, with one in five Europeans now aged 65 or older, projected to approach 30% by 2050. Older adults are more prone to chronic and autoimmune diseases, necessitating comprehensive immune support. Healthcare services are adapting to meet the specific needs of this group, integrating therapies that address immune system vulnerabilities. Regulatory frameworks support the availability of treatments tailored for geriatric care. Continuous advancements in medical education highlight the critical role of immunoglobulin in enhancing life quality among the elderly. Hospitals are expanding immunotherapy units to cater to increased demand, supported by dedicated research programs exploring age-specific applications. The push for seamless patient care experiences includes access to therapies that improve immune function. Elderly-focused healthcare policies emphasize the importance of accessible and effective treatments, driving the systematic inclusion of immunoglobulin in therapeutic regimens.

LATIN AMERICA IMMUNOGLOBULIN MARKET ANALYSIS

Enhanced private healthcare establishments in the region are driving the integration of immunoglobulin therapies. According to International Trade Administration, Brazil is the largest healthcare market in Latin America with 7,191 hospitals, 62% are private. Advanced medical facilities are offering treatments that cater to diverse patient needs. Investments in private sectors are enabling the establishment of state-of-the-art centers equipped with modern therapeutic solutions. Specialized healthcare providers are expanding their service portfolios to include immune-focused therapies. Increased collaboration with global institutions ensures that innovative solutions are implemented swiftly. Educational initiatives are informing professionals about the benefits of advanced treatment modalities, encouraging their inclusion in clinical practice. Such developments ensure that immunoglobulin adoption aligns with the growing expectations of quality care delivery.

MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET ANALYSIS

Upgraded healthcare facilities in the region are propelling immunoglobulin applications across various therapeutic areas. According to Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with 4,482 private medical facilities and 55,208 licensed professionals by 2022, projected to expand further by 3-6% in facilities and 10-15% in professionals in 2023. The establishment of well-equipped medical centers is creating opportunities to include cutting-edge treatments in standard care practices. Regional healthcare improvements emphasize addressing immune deficiencies with effective biotherapeutics. Specialized services within advanced facilities are incorporating immunoglobulin-based interventions to address a wide range of health conditions. Growing emphasis on patient-centric care and the alignment of health services with global standards are fostering widespread therapy utilization. Enhanced accessibility to immune-focused treatments is enabling healthcare providers to cater to broader patient demographics efficiently.

COMPETITIVE LANDSCAPE:

The competitive landscape of the market has key players capturing a significant part of the market share, especially with established networks of plasma collection, advanced manufacturing processes, and strong product portfolios. Intense competition is thus created around product formulations, particularly concerning the development of subcutaneous and IVIG therapies that can advance patient outcomes and convenience. In parallel, continuous efforts are placed on supply chains and increasing capacities to produce goods to meet a growing demand. With these considerations, plasma producers have huge entrance barriers mainly characterized by intricate requirements in the aspect of regulatory laws and rather stringent standards of quality. Companies make considerable mergers and acquisitions for strengthened market position along with strategic partnering. Furthermore, research and development (R&D) for recombinant immunoglobulins, as well as alternate forms of therapies, raise the dynamics of competition within this industry.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What is Immunoglobulin?

2. How big is the immunoglobulin market?

3. What is the expected growth rate of the global Immunoglobulin market during 2026-2034?

4. What are the key factors driving the global Immunoglobulin market?

5. What is the leading segment of the global Immunoglobulin market based on the product?

6. What is the leading segment of the global Immunoglobulin market based on application?

7. What is the leading segment of the global Immunoglobulin market based on the mode of delivery?

8. What are the key regions in the global Immunoglobulin market?

9. Who are the key players/companies in the global Immunoglobulin market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunoglobulin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 IgG
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 IgA
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 IgM
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 IgE
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 IgD
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hypogammaglobulinemia
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunodeficiency Disease
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Myasthenia Gravis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Mode of Delivery

  • 8.1 Intravenous Mode of Delivery
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Subcutaneous Mode of Delivery
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 ADMA Biologics Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Baxter international Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Biotest AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 CSL Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Grifols S.A
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Kedrion S.p.A
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 LFB SA
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Octapharma AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 SWOT Analysis
    • 14.3.9 Sanquin Plasma Products B.V.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Immunoglobulin Market: Major Drivers and Challenges
  • Figure 2: Global: Immunoglobulin Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Immunoglobulin Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Immunoglobulin Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Immunoglobulin Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Immunoglobulin Market: Breakup by Mode of Delivery (in %), 2025
  • Figure 7: Global: Immunoglobulin Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Immunoglobulin (IgG) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Immunoglobulin (IgG) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Immunoglobulin (IgA) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Immunoglobulin (IgA) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Immunoglobulin (IgM) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Immunoglobulin (IgM) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Immunoglobulin (IgE) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Immunoglobulin (IgE) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Immunoglobulin (IgD) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Immunoglobulin (IgD) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Immunoglobulin (Hypogammaglobulinemia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Immunoglobulin (Hypogammaglobulinemia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Immunoglobulin (Chronic Inflammatory Demyelinating Polyneuropathy-CIDP) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Immunoglobulin (Chronic Inflammatory Demyelinating Polyneuropathy-CIDP) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Immunoglobulin (Immunodeficiency Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Immunoglobulin (Immunodeficiency Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Immunoglobulin (Myasthenia Gravis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Immunoglobulin (Myasthenia Gravis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Immunoglobulin (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Immunoglobulin (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Immunoglobulin (Intravenous Mode of Delivery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Immunoglobulin (Intravenous Mode of Delivery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Immunoglobulin (Subcutaneous Mode of Delivery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Immunoglobulin (Subcutaneous Mode of Delivery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: North America: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: North America: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: United States: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: United States: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Canada: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Canada: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Asia-Pacific: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Asia-Pacific: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: China: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: China: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Japan: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Japan: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: India: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: India: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: South Korea: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: South Korea: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Australia: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Australia: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Indonesia: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Indonesia: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Others: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Others: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Europe: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Europe: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Germany: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Germany: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: France: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: France: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: United Kingdom: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: United Kingdom: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Italy: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Italy: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Spain: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Spain: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Russia: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Russia: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Others: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Others: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Latin America: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Latin America: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Brazil: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Brazil: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Mexico: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Mexico: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Middle East and Africa: Immunoglobulin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Middle East and Africa: Immunoglobulin Market: Breakup by Country (in %), 2025
  • Figure 80: Middle East and Africa: Immunoglobulin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Global: Immunoglobulin Industry: SWOT Analysis
  • Figure 82: Global: Immunoglobulin Industry: Value Chain Analysis
  • Figure 83: Global: Immunoglobulin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immunoglobulin Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Immunoglobulin Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Immunoglobulin Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Immunoglobulin Market Forecast: Breakup by Mode of Delivery (in Million USD), 2026-2034
  • Table 5: Global: Immunoglobulin Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Immunoglobulin Market: Competitive Structure
  • Table 7: Global: Immunoglobulin Market: Key Players